Table 1 Patient characteristics according to TDT (< 400 and ≥ 400) (n = 231)
From: Solid component tumor doubling time is a prognostic factor in non-small cell lung cancer patients
All patients | TDT < 400 | TDT ≥ 400 | p-value | |
|---|---|---|---|---|
n = 231 | n = 138 | n = 93 | ||
Age (mean ± SD) | 69.7 ± 9.4 | 70.8 ± 9.2 | 68.2 ± 9.5 | 0.046 |
Sex (Male/Female) | 146 (63.2%)/85 (37.8%) | 100 (72.5%)/38 (27.5%) | 46 (49.5%)/47 (50.5%) | < 0.001 |
Smoking History (Ever/Never) | 138 (59.7%)/93 (40.3%) | 98 (71%)/40 (29%) | 40 (43%)/53 (57%) | < 0.001 |
Serum CEA (mean ± SD) | 4.53 ± 2.7 | 4.7 ± 8.8 | 4.2 ± 8.7 | 0.624 |
Type of resection | ||||
Segmentectomy | 24 (10.4%) | 12 (8.7%) | 12 (12.9%) | 0.428 |
Lobectomy | 206 (89.2%) | 125 (90.6%) | 81 (87.1%) | |
Pneumonectomy | 1 (0.4%) | 1 (0.7%) | 0 | |
Pathological Stage | ||||
IA1 | 49 (21.2%) | 17 (12.3%) | 32 (34.4%) | |
IA2 | 61 (26.4%) | 34 (26.4%) | 27 (29%) | |
IA3 | 20 (8.7%) | 13 (9.4%) | 7 (7.5%) | |
IB | 46 (19.9%) | 31 (22.5%) | 15 (16.1%) | |
IIA | 26 (11.2%) | 21 (15.2%) | 5 (5.4%) | |
IIB | 16 (6.9%) | 12 (8.7%) | 4 (4.3%) | |
IIIA | 13 (5.6%) | 10 (7.2%) | 3 (3.2%) | |
Histological type | ||||
Adenocarcinoma | 163 (70.6%) | 78 (56.5%) | 84 (90.3%) | < 0.001 |
Squamous cell carcinoma | 44 (19%) | 38 (27.5%) | 6 (6.5%) | |
Others | 25 (10.8%) | 22 (15.9%) | 3 (3.2%) | |
Solid component | ||||
Pure solid/Mixed GGO | 114 (49.4%)/117 (50.6%) | 80 (57.8%)/58 (42.2%) | 34 (36.6%)/59 (63.4%) | < 0.001 |
Tumor doubling time (all component) | ||||
Infinite | 24 (10.4%) | |||
range (median, excluding infinite) | 19.14–30,417.42 (230.4) | |||
Tumor doubling time (solid component) | ||||
Infinite | 30 (13%) | |||
range (median, excluding infinite) | 10.73–15,393.04 (175.5) | |||